Objective Patients expressing the tacrolimus-metabolizing enzyme, cytochrome P450 (CYP)
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …

The tacrolimus is metabolized primarily by CYP3A5, a member of the single nucleotide
polymorphism family. It shows cytochrome P450 (SNP) in intron 3, which consists of a …

Background: The pharmacokinetics of tacrolimus (TAC) and mycophenolic acid (MPA) are
highly variable. An impact of single-nucleotide polymorphisms (SNPs) of the genes coding …

What is known and objective Tacrolimus is a widely used immunosuppressive drug with
marked pharmacokinetic variability partly due to CYP 3A5 polymorphism. Our study aimed to …

Cytochrome P450 (CYP) enzymes, such as CYP3A4, and CYP3A5, P450 oxidoreductase
(POR), peroxisome proliferator activated receptor alpha (PPAR-alpha), and drug transporter …

Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine (CsA), play an
essential role in graft survival, preventing rejection. Large interindividual differences in drug …

Methods. In this prospective study, 110 adult kidney transplant recipients treated with
tacrolimus were genotyped for the presence of common SNPs: rs776746: A> G (CYP3A5 …

Background Previous reports have established that patient CYP3A5 allelic variability may be
the most important genetic contributor to interindividual variation in tacrolimus exposure in …

Little is known about the impact of CYP 3A5 polymorphisms on transplantation outcomes
among African American (AA) kidney transplant recipients (KTRs). To assess this issue …

Aim: Tacrolimus is a substrate of CYP3A4 and CYP3A5. The present study investigated the
impact of the CYP3A4* 1/* 1G polymorphism compared with CYP3A5 genotypes on the …